Penn., Jan. 6, 2023 /PRNewswire/ -- Annovis
Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a
clinical-stage drug platform company addressing neurodegenerative
diseases, today announced key additions to its senior leadership
team with the appointments of Dr. Michael
Christie as Vice President of Process Chemistry and
David Prohaska as Vice President of
Toxicology and Pharmacology.
Maria L. Maccecchini, Ph.D., Founder, President, and CEO of
Annovis commented, "The expertise of Dr. Michael Christie and David Prohaska will significantly strengthen our
ability to conduct successful clinical trials and navigate the
regulatory process. The insights and experience that both bring to
Annovis will be instrumental in our success as we take significant
strides in expanding our large-scale manufacturing capabilities,
conduct our late-stage clinical trials in Parkinson's Disease and
Alzheimer's Disease, and satisfy all important regulatory steps
with the FDA."
Michael Christie, Ph.D., brings
to Annovis over 40 years of experience in the pharmaceutical
industry. Dr. Christie formally served as the Senior Director of
Chemical Process and R&D for Teva Pharmaceuticals, where he
directed large teams and managed four laboratories while
coordinating numerous projects and directing the functions of
Chemical Development, Pilot Plant, and Production Laboratory. Prior
to Teva Pharmaceuticals, Dr. Christie served as the Director of
Chemical Process Research and Development at Cephalon, Inc., which
was acquired by Teva Pharmaceuticals in 2011. Dr. Christie also
served as the Vice President of Operations at Puresyn, Inc. and
Vice President of Process Development at Zynaxis Inc.
David Prohaska brings 25 years of
experience in all aspects of preclinical drug development and has a
long track record of successful FDA submissions with multiple drug
approvals. Mr. Prohaska joins Annovis from Aravive Biologics where
he served as the Director of Preclinical Development and Clinical
Operations Support. Prior to Aravive Biologics, Mr. Prohaska served
as the Director of Preclinical Development at Furiex, Inc., where
he was responsible for the preclinical development of several
compounds including eluxadoline.
About Annovis Bio, Inc.
Headquartered in Berwyn,
Pennsylvania, Annovis Bio, Inc.
(Annovis) is a clinical-stage, drug platform company addressing
neurodegeneration, such as Alzheimer's disease (AD), Parkinson's
disease (PD), and other chronic neurodegenerative diseases,
including Alzheimer's in Down Syndrome (AD-DS). We believe that we
are the only company developing a drug for AD, PD, and AD-DS that
inhibits more than one neurotoxic protein and, thereby, improves
the information highway of the nerve cell, known as axonal
transport. When this information flow is impaired, the nerve cell
gets sick and dies. Annovis conducted two Phase 2 studies: one in
AD patients and one in both AD and PD patients. In the AD/PD study
buntanetap showed improvements in cognition and memory in AD as
well as body and brain function in PD patients.
For more information on Annovis Bio, please visit the Company's
website www.annovisbio.com and follow us
on LinkedIn and Twitter.
Statements in this press
release contain "forward-looking statements" that are subject to
substantial risks and uncertainties. Forward-looking statements
contained in this press release may be identified by the use of
words such as "anticipate," "expect," "believe," "will," "may,"
"should," "estimate," "project," "outlook," "forecast" or other
similar words, and include, without limitation, statements
regarding the expected effectiveness of buntanetap and the timing,
effectiveness, and anticipated results of buntanetap clinical
trials. Forward-looking statements are based on Annovis Bio, Inc.'s
current expectations and are subject to inherent uncertainties,
risks and assumptions that are difficult to predict. Further,
certain forward-looking statements are based on assumptions as to
future events that may not prove to be accurate. These and other
risks and uncertainties are described more fully in the section
titled "Risk Factors" in the Annual Report on Form 10-K for the
year ended December 31, 2021, filed with the Securities and
Exchange Commission. Forward-looking statements contained in this
announcement are made as of this date, and Annovis Bio, Inc.
undertakes no duty to update such information except as required
under applicable law.
Russo Partners, LLC
View original content to download
SOURCE Annovis Bio